<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04790045</url>
  </required_header>
  <id_info>
    <org_study_id>PS-CLL-005</org_study_id>
    <nct_id>NCT04790045</nct_id>
  </id_info>
  <brief_title>Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens</brief_title>
  <acronym>LymBIO</acronym>
  <official_title>Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paolo Ghia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      CLL subjects who should receive treatment with a venetoclax-based regimen as per standard of&#xD;
      care will be enrolled into this trial, after providing informed consent.&#xD;
&#xD;
      The following evaluations will be performed baseline before starting treatment:&#xD;
&#xD;
      Baseline assessments:&#xD;
&#xD;
      In addition to standard staging procedures before treatment initiation, including blood tests&#xD;
      and BM aspirate and biopsy, the following procedures will be performed per protocol:&#xD;
&#xD;
        -  Peripheral blood sample drawing for pharmacodynamics studies, MRD assessment and cfDNA&#xD;
           evaluation&#xD;
&#xD;
        -  Ultrasound-guided lymph node CNB&#xD;
&#xD;
        -  Tailored ultrasound evaluation of nodal sites and spleen&#xD;
&#xD;
        -  Bone marrow MRD sample drawing (optional) The nodal site for the biopsy will be selected&#xD;
           based on the size (the largest nodal lesion will be considered) and the procedure&#xD;
           feasibility (only superficial cervical, axillary or inguinal lymph nodes will be&#xD;
           considered suitable for biopsy).&#xD;
&#xD;
      On treatment assessments:&#xD;
&#xD;
      Peripheral blood sampling and ultrasound-guided lymph node CNB will be repeated in patients&#xD;
      on venetoclax-based therapy:&#xD;
&#xD;
        -  7 days after completion of venetoclax ramp up phase,&#xD;
&#xD;
        -  +12 months after completion of venetoclax ramp-up phase. Patients with residual lymph&#xD;
           nodes that are not suitable for ultrasound-guided lymph node CNB will continue the&#xD;
           ultrasound monitoring only&#xD;
&#xD;
      Patients will follow an intensive ultrasound monitoring schedule, which requires tailored&#xD;
      ultrasound evaluation being repeated at the following timepoints:&#xD;
&#xD;
        -  4 weeks after venetoclax ramp-up completion&#xD;
&#xD;
        -  Every 2 months thereafter until disease progression or unacceptable toxicity leading to&#xD;
           permanent treatment discontinuation.&#xD;
&#xD;
      Assessments at progression:&#xD;
&#xD;
      A tailored ultrasound of nodal sites and spleen will be performed within 2 weeks from the&#xD;
      first signs and/or symptoms of suspected progression. US assessment can be delayed at&#xD;
      Investigator's discretion in case pseudo-progression is suspected based on potentially&#xD;
      confounding concomitant conditions, e.g. infection.&#xD;
&#xD;
      In progressive cases, the same assessments (including BM aspirate and biopsy) will be&#xD;
      repeated at the time of disease progression.&#xD;
&#xD;
      In patients progressing with bulky lymph nodes an incisional lymph node biopsy (instead of an&#xD;
      ultrasound-guided CNB) will be performed to exclude Richter's transformation as per standard&#xD;
      of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LN, PB and BM mononuclear cells collected from CLL patients at specified timepoints will be&#xD;
      tested by:&#xD;
&#xD;
        -  High-throughput ex vivo drug assay (2D platforms)&#xD;
&#xD;
        -  Global transcriptome analysis by RNA sequencing&#xD;
&#xD;
        -  Flow cytometry including activation and adhesion/migration markers, e.g. CD69, CD80,&#xD;
           CD86, HLA-DR, CD38, CD49d, CXCR4;&#xD;
&#xD;
        -  Phospho-flow assays, to assess the phosphorylation state of proteins involved in BCR&#xD;
           signaling transduction, e.g. AKT and ERK;&#xD;
&#xD;
        -  Western blot of nuclear lysates and cytoplasmic protein fractions to validate the&#xD;
           expression of relevant genes&#xD;
&#xD;
        -  Targeted deep-sequencing by a previously validated panel&#xD;
&#xD;
      Minimal residual disease evaluation will be performed by:&#xD;
&#xD;
        -  6-color flow cytometry&#xD;
&#xD;
        -  NGS CfDNA will be analysed by targeted NGS.&#xD;
&#xD;
      The following features will be evaluated by tailored ultrasound:&#xD;
&#xD;
      Superficial nodal sites (linear probe 7.5 MHz):&#xD;
&#xD;
        -  Site&#xD;
&#xD;
        -  Size: long and short diameter (sensitivity &lt;5 mm)&#xD;
&#xD;
        -  Shape&#xD;
&#xD;
        -  Border&#xD;
&#xD;
        -  echo-structure of the cortex; assessment of possible intranodal reticulation&#xD;
&#xD;
        -  Echogenic description of the hilum: presence, absence and irregular echo-morphology&#xD;
&#xD;
      Optional parameters:&#xD;
&#xD;
        -  Doppler evaluation: vascular distribution, vascular resistance&#xD;
&#xD;
        -  Contrast enhanced ultrasound (CEUS): 7.5 MHz linear probe (optional);Quantitative&#xD;
           assessment with dedicated software (wash-in and wash-out curves): optional&#xD;
&#xD;
      Deep nodal sites (probe 3.5-5 MHz):&#xD;
&#xD;
        -  Site&#xD;
&#xD;
        -  Presence/absence of deep lymphoadenopathies&#xD;
&#xD;
        -  Size (sensitivity &lt;5 mm)&#xD;
&#xD;
        -  Echo-structure of the cortex (only if superficial, e.g. external iliac LN)&#xD;
&#xD;
      Optional parameters:&#xD;
&#xD;
        -  Vascular pattern by: color doppler, two-dimensional power doppler and MicroV (only if&#xD;
           superficial, e.g. external iliac LN)&#xD;
&#xD;
        -  Contrast enhanced ultrasound (CEUS) (optional): vascular pattern present vs absent,&#xD;
           intensity&#xD;
&#xD;
      Spleen:&#xD;
&#xD;
        -  Size (dedicated software to more precisely define the bipolar diameter) : in cm&#xD;
&#xD;
        -  Cross sectional area in cm2&#xD;
&#xD;
      Optional parameters:&#xD;
&#xD;
        -  Splenic artery resistive index&#xD;
&#xD;
        -  Portal vein flow (forward or non-forward portal flow): Vmax (&quot;maximum velocity expressed&#xD;
           in cm&quot; and &quot;mean Velocity expressed in cm&quot;)&#xD;
&#xD;
        -  Splenic stiffness (with Fibroscan or point share wave or share wave 2D) expressed in kPa&#xD;
&#xD;
      Liver:&#xD;
&#xD;
        -  Size&#xD;
&#xD;
        -  Echo-structure&#xD;
&#xD;
      Optional parameters:&#xD;
&#xD;
        -  Portal vein flow parameters&#xD;
&#xD;
        -  Liver artery resistive index&#xD;
&#xD;
        -  Liver stiffness expressed in kPa&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate lymph node changes in CLL patients treated with venetoclax-based regimens both at molecular level</measure>
    <time_frame>24 months</time_frame>
    <description>Gene expression profile of CLL cells derived from lymph nodes of patients treated with venetoclax-based regimens</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate lymph node changes in CLL patients treated with venetoclax-based regimens both at ultrasound level</measure>
    <time_frame>24 months</time_frame>
    <description>Ultrasound characteristics of lymph nodes of patients treated with venetoclax-based regimens</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Venetoclax-based treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single-arm study Patients enrolled will be receiving venetoclax-based regimens according to the standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Core-needle biopsy to be performed before starting treatment in patients candidates to venetoclax-based regimens</description>
    <arm_group_label>Venetoclax-based treatment</arm_group_label>
    <other_name>core-needle biopsy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CLL diagnosis&#xD;
&#xD;
          -  Patients receiving treatment with venetoclax-based regimens&#xD;
&#xD;
          -  Baseline platelet value &gt;100x109/l&#xD;
&#xD;
          -  PT INR and aPTT within normal range&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Patients receiving anticoagulant or antiplatelet treatment that cannot be safely&#xD;
        interrupted before the biopsy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 28, 2021</study_first_submitted>
  <study_first_submitted_qc>March 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Paolo Ghia</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

